Polycythaemia vera is associated with a reduced quality of life, a high rate of vascular
events, and an intrinsic risk of disease evolution. The results of several randomised trials for …

Abstract Disease Overview Polycythemia vera (PV) is a JAK2‐mutated myeloproliferative
neoplasm characterized by clonal erythrocytosis; other features include leukocytosis …

Disease overview Polycythemia vera (PV) and essential thrombocythemia (ET) are
myeloproliferative neoplasms (MPN) respectively characterized by clonal erythrocytosis and …

Essential thrombocythemia is a Janus kinase 2 (JAK2) mutation-prevalent myeloproliferative
neoplasm characterized by clonal thrombocytosis; clinical course is often indolent but might …

The 2011 approval of ruxolitinib ushered in the Janus kinase (JAK) inhibitor era in the
treatment of myelofibrosis (MF), and 2019 saw the US approval of fedratinib. The first …

Hydroxyurea (hydroxycarbamide) is approved for treating both children and adults with
sickle cell anaemia (SCA). Fetal haemoglobin (HbF) induction is the primary treatment …

Abstract Purpose of Review This review focuses on vascular complications associated with
chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the …

Myeloproliferative neoplasms (MPNs) have estimated annual incidence rates for
polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis of 0.84 …

Ruxolitinib (RUX), the first JAK1/JAK2 inhibitor approved for myelofibrosis (MF) therapy, has
recently been associated with the occurrence of second primary malignancies (SPMs) …

Simple Summary Patients with chronic myeloproliferative neoplasms (MPNs) such as
polycythemia vera and essential thrombocythemia have an elevated risk of acute leukemia …